Trial Profile
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms C-ISLE
- Sponsors Merck Sharp & Dohme Corp.
- 23 Feb 2018 Results published in the Hepatology
- 09 May 2017 Final results of the C-Isle Study, presented at the Digestive Disease Week 2017
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.